CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade scPharmaceuticals Inc. - SCPH CFD

    5.30
    2.02%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    scPharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 5.45
    Open* 5.39
    1-Year Change* -23.65%
    Day's Range* 5.33 - 5.44
    52 wk Range 4.63-12.75
    Average Volume (10 days) 449.65K
    Average Volume (3 months) 5.14M
    Market Cap 201.90M
    P/E Ratio -100.00K
    Shares Outstanding 35.86M
    Revenue 7.50M
    EPS -1.36
    Dividend (Yield %) N/A
    Beta 0.13
    Next Earnings Date Mar 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 5.45 0.13 2.44% 5.32 5.47 5.24
    Nov 30, 2023 5.40 0.00 0.00% 5.40 5.55 5.33
    Nov 29, 2023 5.44 -0.14 -2.51% 5.58 5.68 5.42
    Nov 28, 2023 5.39 -0.05 -0.92% 5.44 5.50 5.32
    Nov 27, 2023 5.47 -0.21 -3.70% 5.68 5.68 5.43
    Nov 24, 2023 5.68 0.37 6.97% 5.31 5.81 5.31
    Nov 22, 2023 5.46 -0.21 -3.70% 5.67 5.68 5.34
    Nov 21, 2023 5.60 0.04 0.72% 5.56 5.90 5.41
    Nov 20, 2023 5.58 0.45 8.77% 5.13 5.73 5.13
    Nov 17, 2023 5.22 0.31 6.31% 4.91 5.22 4.91
    Nov 16, 2023 4.98 0.02 0.40% 4.96 5.05 4.81
    Nov 15, 2023 5.01 -0.01 -0.20% 5.02 5.18 4.92
    Nov 14, 2023 5.06 0.24 4.98% 4.82 5.14 4.82
    Nov 13, 2023 4.96 0.18 3.77% 4.78 5.01 4.66
    Nov 10, 2023 4.87 0.21 4.51% 4.66 4.97 4.62
    Nov 9, 2023 4.66 -0.18 -3.72% 4.84 5.02 4.57
    Nov 8, 2023 5.11 0.13 2.61% 4.98 5.17 4.97
    Nov 7, 2023 5.10 -0.06 -1.16% 5.16 5.26 5.06
    Nov 6, 2023 5.26 -0.03 -0.57% 5.29 5.37 5.15
    Nov 3, 2023 5.32 0.31 6.19% 5.01 5.41 5.01

    scPharmaceuticals Inc. Events

    Time (UTC) Country Event
    Wednesday, March 20, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 scPharmaceuticals Inc Earnings Release
    Q4 2023 scPharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 36.157 25.823 29.933 32.905 29.667
    Selling/General/Admin. Expenses, Total 20.624 9.784 11.784 8.273 13.719
    Research & Development 15.533 16.039 18.149 24.632 15.948
    Operating Income -36.157 -25.823 -29.933 -32.905 -29.667
    Interest Income (Expense), Net Non-Operating -2.099 -2.526 -2.272 -0.107 0.28
    Other, Net 1.418 0.315 -0.004 0.016 -0.056
    Net Income Before Taxes -36.838 -28.034 -32.209 -32.996 -29.443
    Net Income After Taxes -36.838 -28.034 -32.209 -32.996 -29.443
    Net Income Before Extra. Items -36.838 -28.034 -32.209 -32.996 -29.443
    Net Income -36.838 -28.034 -32.209 -32.996 -29.443
    Income Available to Common Excl. Extra. Items -36.838 -28.034 -32.209 -32.996 -29.443
    Income Available to Common Incl. Extra. Items -36.838 -28.034 -32.209 -32.996 -29.443
    Dilution Adjustment
    Diluted Net Income -36.838 -28.034 -32.209 -32.996 -29.443
    Diluted Weighted Average Shares 28.3585 24.5689 24.5689 18.6007 18.5561
    Diluted EPS Excluding Extraordinary Items -1.29901 -1.14104 -1.31097 -1.77391 -1.5867
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -1.29901 -1.14104 -1.31097 -1.77391 -1.5867
    Total Extraordinary Items
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1.638 2.063 0 0 0
    Total Operating Expense 15.384 13.617 9.502 9.995 9.421
    Selling/General/Admin. Expenses, Total 12.096 10.896 7.176 6.277 4.279
    Research & Development 2.934 2.116 2.326 3.718 5.142
    Operating Income -13.746 -11.554 -9.502 -9.995 -9.421
    Interest Income (Expense), Net Non-Operating -0.647 -0.646 -1.109 -0.145 -0.34
    Other, Net 0.239 0.99 1.363 -0.022 0.064
    Net Income Before Taxes -14.154 -11.21 -9.248 -10.162 -9.697
    Net Income After Taxes -14.154 -11.21 -9.248 -10.162 -9.697
    Net Income Before Extra. Items -14.154 -11.21 -9.248 -10.162 -9.697
    Net Income -14.154 -11.21 -9.248 -10.162 -9.697
    Income Available to Common Excl. Extra. Items -14.154 -11.21 -9.248 -10.162 -9.697
    Income Available to Common Incl. Extra. Items -14.154 -11.21 -9.248 -10.162 -9.697
    Diluted Net Income -14.154 -11.21 -9.248 -10.162 -9.697
    Diluted Weighted Average Shares 38.6926 37.801 31.2857 27.4011 27.3785
    Diluted EPS Excluding Extraordinary Items -0.36581 -0.29655 -0.2956 -0.37086 -0.35418
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.36581 -0.29655 -0.2956 -0.37086 -0.35418
    Revenue 1.638 2.063
    Cost of Revenue, Total 0.354 0.605
    Gross Profit 1.284 1.458
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 123.308 78.275 107.826 75.647 91.893
    Cash and Short Term Investments 118.186 75.278 105.095 72.624 89.478
    Cash & Equivalents 71.061 74.268 71.819 72.624 89.478
    Total Receivables, Net 0.31 0.479
    Prepaid Expenses 2.282 2.791 2.61 2.619 1.757
    Other Current Assets, Total 1.61 0.206 0.121 0.094 0.179
    Total Assets 124.195 79.037 109.048 77.283 93.755
    Property/Plant/Equipment, Total - Net 0.62 0.479 0.908 1.306 1.67
    Property/Plant/Equipment, Total - Gross 0.808 0.649 1.044 1.408 2.27
    Accumulated Depreciation, Total -0.188 -0.17 -0.136 -0.102 -0.6
    Other Long Term Assets, Total 0.267 0.283 0.314 0.33 0.192
    Total Current Liabilities 7.416 14.846 9.321 5.237 6.673
    Accounts Payable 1.518 0.544 1.666 1.142 0.587
    Accrued Expenses 5.807 4.466 5.207 4.046 3.11
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.091 0.031 0.04 0.049 0.165
    Total Liabilities 51.762 22.567 26.878 25.918 15.011
    Total Long Term Debt 36.794 7.354 16.858 18.915 6.826
    Other Liabilities, Total 7.552 0.367 0.699 1.766 1.512
    Total Equity 72.433 56.47 82.17 51.365 78.744
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.003 0.003 0.003 0.002 0.002
    Additional Paid-In Capital 298.934 246.166 243.83 180.818 175.201
    Retained Earnings (Accumulated Deficit) -226.536 -189.698 -161.664 -129.455 -96.459
    Total Liabilities & Shareholders’ Equity 124.195 79.037 109.048 77.283 93.755
    Total Common Shares Outstanding 34.2579 27.3667 27.326 19.419 18.5693
    Current Port. of LT Debt/Capital Leases 0 9.805 2.408 0 2.811
    Long Term Debt 36.794 7.354 16.858 18.915 6.826
    Short Term Investments 47.125 1.01 33.276
    Other Equity, Total 0.032 -0.001 0.001
    Total Inventory 1.23
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 104.339 113.574 126.667 123.308 47.169
    Cash and Short Term Investments 90.198 102.877 116.071 118.186 45.186
    Cash & Equivalents 35.042 71.35 75.453 71.061 41.289
    Short Term Investments 55.156 31.527 40.618 47.125 3.897
    Prepaid Expenses 1.579 1.835 2.685 2.282 1.643
    Other Current Assets, Total 1.264 1.42 1.286 1.61 0.34
    Total Assets 106.101 114.171 127.371 124.195 48.4
    Property/Plant/Equipment, Total - Net 1.574 0.408 0.514 0.62 0.739
    Property/Plant/Equipment, Total - Gross 1.78 0.608 0.708 0.808 0.919
    Accumulated Depreciation, Total -0.206 -0.2 -0.194 -0.188 -0.18
    Other Long Term Assets, Total 0.188 0.189 0.19 0.267 0.492
    Total Current Liabilities 10.951 6.635 7.735 7.416 17.176
    Accounts Payable 3.37 1.182 1.626 1.518 0.996
    Accrued Expenses 7.181 5.23 5.857 5.807 5.772
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 9.88
    Other Current Liabilities, Total 0.4 0.223 0.252 0.091 0.528
    Total Liabilities 56.955 50.744 51.564 51.762 17.29
    Total Long Term Debt 38.262 37.741 37.252 36.794 0
    Long Term Debt 38.262 37.741 37.252 36.794 0
    Other Liabilities, Total 7.742 6.368 6.577 7.552 0.114
    Total Equity 49.146 63.427 75.807 72.433 31.11
    Common Stock 0.004 0.004 0.004 0.003 0.003
    Additional Paid-In Capital 316.678 315.329 313.541 298.934 248.395
    Retained Earnings (Accumulated Deficit) -267.534 -251.9 -237.746 -226.536 -217.288
    Other Equity, Total -0.002 -0.006 0.008 0.032 0
    Total Liabilities & Shareholders’ Equity 106.101 114.171 127.371 124.195 48.4
    Total Common Shares Outstanding 35.8591 35.8495 35.7691 34.2579 27.4021
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Total Inventory 7.123 5.832 3.621 1.23
    Total Receivables, Net 4.175 1.61 3.004
    Accounts Receivable - Trade, Net 4.175 1.61 3.004
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -36.838 -28.034 -32.209 -32.996 -29.443
    Cash From Operating Activities -34.577 -27.151 -27.693 -30.442 -28.812
    Cash From Operating Activities 0.037 0.034 0.034 0.037 0.038
    Non-Cash Items 2.574 3.448 3.034 2.163 2.803
    Changes in Working Capital -0.35 -2.599 1.448 0.354 -2.21
    Cash From Investing Activities -45.859 32.13 -33.46 0
    Capital Expenditures -0.021 -0.009 0
    Cash From Financing Activities 77.229 -2.53 60.348 13.588 -0.008
    Financing Cash Flow Items -0.054 -0.081 -0.164 0
    Issuance (Retirement) of Stock, Net 47.982 0.051 61.312 4.033 0.054
    Issuance (Retirement) of Debt, Net 29.301 -2.5 -0.8 9.555 -0.062
    Net Change in Cash -3.207 2.449 -0.805 -16.854 -28.82
    Cash Taxes Paid 0.19 0.206 0.226 0.337 0.298
    Cash Interest Paid 2.555 2.043 1.986 1.383 1.059
    Other Investing Cash Flow Items, Total -45.838 32.139 -33.46
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -11.21 -36.838 -27.59 -17.428 -7.731
    Cash From Operating Activities -16.494 -34.577 -22.74 -14.544 -7.369
    Cash From Operating Activities 0.006 0.037 0.028 0.018 0.009
    Non-Cash Items 0.048 2.574 2.69 1.722 0.847
    Cash Taxes Paid 0.069 0.19 0.114 0.114 0.036
    Cash Interest Paid 1.485 2.555 1.099 0.794 0.425
    Changes in Working Capital -5.338 -0.35 2.132 1.144 -0.494
    Cash From Investing Activities 7 -45.859 -2.867 -13.651 -12.79
    Other Investing Cash Flow Items, Total 7 -45.838 -2.846 -13.645 -12.784
    Cash From Financing Activities 13.704 77.229 -7.372 -4.895 -2.479
    Financing Cash Flow Items -0.054 0 0 0
    Issuance (Retirement) of Stock, Net 13.704 47.982 0.128 0.105 0.021
    Net Change in Cash 4.21 -3.207 -32.979 -33.09 -22.638
    Issuance (Retirement) of Debt, Net 0 29.301 -7.5 -5 -2.5
    Capital Expenditures 0 -0.021 -0.021 -0.006 -0.006
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 15.5047 5559528 0 2023-06-30 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 9.1972 3297843 0 2023-06-30 LOW
    Cowen Investment Management LLC Investment Advisor/Hedge Fund 6.7143 2407562 2407562 2023-02-16 HIGH
    Sun Pharmaceutical Industries Ltd Corporation 6.0453 2167679 0 2023-04-11 LOW
    Cowen & Co., LLC Research Firm 5.1257 1837918 -969644 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.4411 1592449 1483942 2023-06-30 LOW
    AIGH Capital Management, LLC. Private Equity 4.2933 1539468 -25681 2023-06-30 MED
    Millennium Management LLC Hedge Fund 3.3918 1216206 -437807 2023-06-30 HIGH
    5AM Ventures Venture Capital 3.3484 1200647 0 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.3271 1193006 193039 2023-06-30 LOW
    Morgan Stanley & Co. LLC Research Firm 2.8812 1033119 -2820 2023-06-30 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.8325 1015638 964078 2023-06-30 LOW
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 2.3886 856477 856477 2023-06-30 LOW
    Jefferies LLC Research Firm 2.3175 831000 -485000 2023-06-30 HIGH
    Rubric Capital Management LP Hedge Fund 2.2632 811517 811517 2023-06-30 MED
    Thrivent Asset Management, LLC Investment Advisor 1.8268 655020 655020 2023-06-30 LOW
    Walleye Capital LLC Hedge Fund 1.5608 559660 559660 2023-06-30 HIGH
    Luther King Capital Management Corp. Investment Advisor 1.5588 558925 144425 2023-06-30 LOW
    Worth Venture Partners, LLC Investment Advisor/Hedge Fund 1.4288 512337 1689 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.243 445714 274270 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    scPharmaceuticals Inc. Company profile

    About Scpharmaceuticals Inc

    scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The Company's wholly owned subsidiary is scPharmaceuticals Securities Corporation.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Scpharmaceuticals Inc revenues was not reported. Net loss decreased 15% to $20.7M. Lower net loss reflects Research and development - Balancing decrease of 22% to $10.8M (expense), General and administrative - Balancing decrease of 9% to $6.6M (expense), Other income (expense) increase from $13K (expense) to $298K (income).

    Industry: Pharmaceuticals (NEC)

    2400 District Avenue
    Suite 310
    BURLINGTON
    MASSACHUSETTS 01803
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    74.69 Price
    -0.380% 1D Chg, %
    Long position overnight fee -0.0137%
    Short position overnight fee -0.0082%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    2,024.77 Price
    -1.680% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    15,719.80 Price
    -1.630% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    41,324.40 Price
    +4.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading